IPIX (Innovation Pharmaceuticals) ROC %: -52.95% (As of Sep. 2023)

What is Innovation Pharmaceuticals ROC %?

Innovation Pharmaceuticals IPIX ROC % is -52.95% as of Sep. 2023.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Innovation Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Sep. 2023 was -52.95%.

As of today (2026-06-25), Innovation Pharmaceuticals's WACC % is 0.00%. Innovation Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Innovation Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Innovation Pharmaceuticals (OTCPK:IPIX) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Innovation Pharmaceuticals's WACC % is 0.00%. Innovation Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Innovation Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Innovation Pharmaceuticals ROC % Related Terms

Innovation Pharmaceuticals ROC % Historical Data

* Premium members only.

The historical data trend for Innovation Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation Pharmaceuticals ROC % Chart

Innovation Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROC %

Get a 7-Day Free Trial

-112.00

-88.12

-173.25

-111.67

-45.13

Innovation Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROC %	Get a 7-Day Free Trial															-81.46	-20.09	-39.57	-37.16	-52.95

Innovation Pharmaceuticals ROC % Calculation

Innovation Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Jun. 2023 is calculated as:

	ROC % (A: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Jun. 2022 )	+	Invested Capital (A: Jun. 2023 ))	/ count )
=	-2.939 * ( 1 - 0% )	/	( (6.874	+	6.151)	/ 2 )
=	-2.939	/	6.5125
=	-45.13 %

where

	Invested Capital		(A: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.379	-	4.361	-	( 3.807	-	max(0, 4.808	-	3.952	+	3.807	))
=	6.874

	Invested Capital		(A: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.517	-	4.753	-	( 1.518	-	max(0, 5.021	-	1.634	+	1.518	))
=	6.151

Innovation Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-3.208 * ( 1 - 0% )	/	( (6.151	+	5.965)	/ 2 )
=	-3.208	/	6.058
=	-52.95 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.517	-	4.753	-	( 1.518	-	max(0, 5.021	-	1.634	+	1.518	))
=	6.151

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6.667	-	4.81	-	( 0.864	-	max(0, 5.048	-	0.94	+	0.864	))
=	5.965

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -52.95% mean?

Innovation Pharmaceuticals (IPIX) has a ROC % of -52.95% as of Sep. 2023. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Innovation Pharmaceuticals and its competitors.

Is Innovation Pharmaceuticals' ROC % too high?

Innovation Pharmaceuticals' current ROC % is -52.95%.

How does Innovation Pharmaceuticals' ROC % compare to AXIM and RNAZ?

Innovation Pharmaceuticals' ROC % of -52.95% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Innovation Pharmaceuticals and its competitors. Innovation Pharmaceuticals's current ROC % is -52.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Innovation Pharmaceuticals stock overvalued right now?

Innovation Pharmaceuticals (IPIX) has a current ROC % of -52.95%. The current ROC % is -52.95%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current ROC % is -52.95% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies AXIM RNAZ APTX CPMV VRAX KPRX NEXI QRON ENDV ENVB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880

Website http://www.ipharminc.com

Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.